Company Filing History:
1 out of 4 
1 out of 3 
1 out of 832,843 Years Active: 2014
Title: The Innovative Contributions of Giulio Fracasso in Cancer Research
Introduction
Giulio Fracasso, based in Verona, Italy, is a notable inventor known for his groundbreaking work in cancer research. With a focus on targeted therapies, Fracasso has made significant strides in the development of innovative treatments aimed at improving patient outcomes. His most prominent patent embodies his commitment to advancing the field of oncology.
Latest Patents
Fracasso holds a patent for an "Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof." This invention details an isolated monoclonal antibody that binds specifically to the prostate specific membrane antigen (PSMA), typically found on the surface of tumor cells. The patent elaborates on the use of the complete antibody and its fragment, either alone or conjugated with active ingredients, for the treatment and diagnosis of tumors, particularly those associated with prostate cancer. This innovative approach positions Fracasso's work at the forefront of therapeutic development in prostatic neoplastic diseases.
Career Highlights
Throughout his career, Giulio Fracasso has been associated with reputable institutions, including the University of Verona (Università Degli Studi Di Verona) and the National Institute of Tumors Foundation (Fondazione IRCCS “Istituto Nazionale dei Tumori”). His contributions to these institutions emphasize his dedication to cancer research and the advancement of medical science.
Collaborations
Fracasso has collaborated with several talented individuals in the field. Notable among his colleagues are Marco Colombatti and Sara Cingarlini. These collaborations have fostered an environment of innovative thinking and have been crucial in translating research findings into potential clinical applications.
Conclusion
Giulio Fracasso's inventive spirit and commitment to cancer research exemplify the profound impact that dedicated scientists can have on medical advancements. His patented work with monoclonal antibodies represents a significant contribution to the diagnosis and treatment of prostate cancer, promising hope to many patients. As the field of oncology continues to evolve, Fracasso's innovations will undoubtedly play a vital role in shaping future therapeutic strategies.